Entwicklungen und gegenwärtige Situationen der Covid-19-Impfstoffe
26 July 2021
These organisations have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly for low- and middle-income countries.
The aim is to vaccinate at least 40 percent of people in every country by the end... of 2021, and at least 60 percent by mid-2022. The effort will track, coordinate, and advance delivery of COVID-19 vaccines, therapeutics and diagnostics, working with governments and partners at the global and local levels to address finance and trade barriers to ensure that vulnerable populations have access to these life-saving tools. It supports the goals of the ACT-Accelerator and complementary initiatives.
more
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
21.12.2020
Available in English, Spanish, Italian and Portuguese
Sep 22, 2021.
In our updated analysis we find that, as of September 9, there continue to be wide disparities in access and at current rates, most low-income countries (LICs) and most countries in Africa will not reach global vaccination targets. We also find that, compared to July, the rate at whic...h vaccination would have to increase for LICs to meet global targets is even greater now, due to more ambitious goals and continued low rates of dose administration in these countries.
more
This inter-agency guidance document aims to supplement the COVAX demand creation package for COVID-19 vaccines with key considerations for humanitarian contexts and marginalized populations with specific access and communication needs.
21 Sept.2021
For most people in displacement contexts, there are simply not enough vaccines available in the places where they are hosted: 85% of refugees are hosted in lower- and middle-income countries, while in the first six months of this year 85% of vaccines went to wealthy countries; lower- and middle inco...me countries have still received only a fraction of the vaccine doses they require.3 Shortages in these countries can also pose particular risks to vaccination campaigns aimed at displaced populations, as they can result in them being deprioritized.
more
Oct 6, 2021. Entschlossene Solidarität oder endlose Krise.
Vortrag für: Tag der Forschung und Beratung der kath. Universität von Misiones (UCAMI), Argentinien
The unparalleled action needed to combat unprecedented inequality in the wake of COVID-19.
New billionaire minted every 26 hours, as inequality contributes to the death of one person every four seconds
Available in English, French, Spanish and Arabic https://www.oxfam.org/en/research/inequality-ki...lls
more
The unparalleled action needed to combat unprecedented inequality in the wake of COVID-19.
New billionaire minted every 26 hours, as inequality contributes to the death of one person every four seconds
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...of five leading vaccine manufacturers, AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc. It also includes for the first time an assessment of the two largest Chinese vaccine producers, China National Pharmaceutical Group Co., Ltd. (Sinopharm) and Sinovac Biotech Ltd. (Sinovac).
more
22 Sept. 2021
The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisi...ve role in restricting fair access to a life-saving health product. This report focuses on six leading vaccine developers, AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax and Pfizer, assessing each company’s human rights policy, pricing structure, records on intellectual property, knowledge and technology sharing, allocation of available vaccine doses and transparency.
Available in Arabic, English, French, German and Spanish
more
This research report offers community perceptions of COVID-19 from migrants, refugees, host communities and indigenous populations in nine countries in the Americas: Argentina, Brazil, Bolivia, Colombia, Guatemala, Nicaragua, Jamaica, Panama and Trinidad and Tobago.
It reveals the myriad impacts ...that COVID-19 has had, and continues to have, on vulnerable and hard-to-reach populations. And it offers hands-on recommendations around the impact and usefulness of health information; trust, awareness and access to vaccines; and the socio-economic impact of the pandemic.
more
Data for Action March 2022, Issue 5
Global Fund Strategy 2023-2028
Available in different languages from the website https://www.theglobalfund.org/en/publications/
This report’s central premise is that diagnostics and therapeutics, and associated test to treat strategies, are fundamental components of the pandemic response, both for COVID-19 and for future health threats. Two years into the COVID-19 pandemic, this report reflects on the main challenges and k...ey solutions on the road to equitable access to diagnostics and therapeutics.
This report draws from experience gained through the Access to COVID-19 Tools (ACT) Accelerator Diagnostics and Therapeutics pillars, and includes the perspectives of collaborating stakeholders (countries, civil society representatives and the private sector). Building on these findings, this report proposes sixteen recommended actions to address what have been identified as key structural challenges and specifies a potential owner for each action.
more
Despite high regional demand for vaccines valued at over US$ 1 billion annually, Africa’s vaccine industry provides only 0.1% of global supply. Vaccine inequity and hoarding at the start of the pandemic, which resulted in delays in obtaining COVID-19 doses, stimulated new resolve to address future... supply security. In 2021, the AU set a target to produce and supply more than 60% of the vaccine doses on the continent by 2040.
In the last 18 months alone, more than 30 new African manufacturing projects have been announced and estimates indicate that the African vaccine market across all existing and projected novel products could range between US$ 2.8 billion and US$ 5.6 billion by 2040*, demonstrating the potential for a thriving regional industry to emerge.
more
The report aims to capture lessons from the COVID-19 pandemic and to highlight the opportunity for more ambitious global action: expanding sustainable access to vaccines for all towards
the Immunization Agenda 2030 and pandemic prevention, preparedness and response efforts. The report is organized ...in two sections: the first section provides WHO insights on global vaccine market dynamics, drawing from data provided by Member States, which are, in turn, analysed and displayed in the second section.
more
La lutte contre l’épidémie de Covid-19 nous montre de manière cinglante que, sur le terrain de l’action en santé publique, les logiques de promotion de la santé sont bel et bien minoritaires. Pendant cette période de crise, la décision
politique et sanitaire se base largement sur un mod...le hygiéniste. Ce dernier s’est déployé comme si la promotion de la santé (appelée à devenir à ses origines une «nouvelle santé publique») n’avait jamais existé, comme si tout un corpus
d’enseignements n’avait pu franchir les murs des écoles, comme si un ensemble de pratiques menées depuis un demi-siècle à différentes échelles n’avaient pas démontré leur efficacité et été reconnues scientifiquement.
more